山东大学耳鼻喉眼学报 ›› 2025, Vol. 39 ›› Issue (5): 148-155.doi: 10.6040/j.issn.1673-3770.0.2023.334

• 综述 • 上一篇    下一篇

补体在喉鳞状细胞癌发生发展中作用机制的研究进展

胡祎1,孔旭辉2   

  1. 1.南通大学 医学院, 江苏 南通 226001;
    2.南京医科大学附属泰州人民医院 耳鼻咽喉头颈外科, 江苏 泰州 225300
  • 发布日期:2025-09-19
  • 通讯作者: 孔旭辉. E-mail:1546732829@qq.com
  • 基金资助:
    泰州市人民医院2021年度科研启动基金项目(QDJJ202105)

Research progress on the mechanism of complement in the development of laryngeal squamous cell carcinoma

HU Yi1, KONG Xuhui2   

  1. 1. Department of Otolaryngology, Nantong University Medical School, Nantong 226001, Jiangsu, China2. Department of Otorhinolaryngology & Head and Neck Surgery, Taizhou People's Hospital of Nanjing Medical University, Taizhou 225300, Jiangsu, China
  • Published:2025-09-19

PDF (PC)

170

摘要： 补体系统是免疫系统的重要组成部分,参与多种疾病,如自身免疫性疾病、感染性疾病、风湿性疾病、血液系统疾病和癌症的发生及发展。喉癌是常见的头颈部恶性肿瘤之一,研究补体影响喉鳞状细胞癌相关机制,并从中寻找有效的生物标志物,将有助于提高对喉鳞状细胞癌的诊断、治疗能力。本文简要综述补体系统的激活,并从肿瘤微环境、肿瘤细胞本身及其分泌物层面阐述了补体蛋白如何影响喉鳞状细胞癌发生发展及转移,为进一步研究喉鳞癌靶向治疗的临床应用提供参考。

关键词: 补体系统, 喉鳞状细胞癌, 肿瘤微环境, 上皮间质转化

Abstract: The complement system is an important part of the immune system and is involved in the occurrence and development of a variety of diseases such as autoimmune diseases, infectious diseases, rheumatic diseases, blood diseases, and cancer. Laryngeal cancer the common malignancy of the head and neck Studying the mechanism whereby complement affects laryngeal squamous cell carcinoma and identifying effective biomarkers will help improve the diagnosis and treatment of laryngeal squamous cell carcinoma. This article briefly reviews the activation of the complement system, and explains how complement proteins affect the development and metastasis of laryngeal squamous cell carcinoma from the levels of the tumor microenvironment and the tumor cells themselves and their secretions, to provide a reference for further research on the clinical application of targeted therapy for laryngeal squamous cell carcinoma.

Key words: Complement system, Laryngeal squamous cell carcinoma, Tumor microenvironment, Epithelial- mesenchymal transition

中图分类号: 

  • R739.65
[1] Liberale C, Soloperto D, Marchioni A, et al. Updates on larynx cancer: risk factors and oncogenesis[J]. Int J Mol Sci, 2023, 24(16): 12913. doi:10.3390/ijms241612913
[2] He YT, Liang D, Li DJ, et al. Incidence and mortality of laryngeal cancer in China, 2015[J]. Chin J Cancer Res, 2020, 32(1): 10-17. doi:10.21147/j.issn.1000-9604.2020.01.02
[3] 黄海涛, 耿旭, 尚艳秋, 等. 2005—2016年中国喉癌发病及死亡趋势分析[J]. 中国全科医学, 2022, 25(5): 608-614. doi:10.12114/j.issn.1007-9572.2021.01.047 HUANG Haitao, GENG Xu, SHANG Yanqiu, et al. Trends of laryngeal cancer incidence and mortality in China, 2005—2016[J]. Chinese General Practice, 2022, 25(5): 608-614. doi:10.12114/j.issn.1007-9572.2021.01.047
[4] Romano R, Giardino G, Cirillo E, et al. Complement system network in cell physiology and in human diseases[J]. Int Rev Immunol, 2021, 40(3): 159-170. doi:10.1080/08830185.2020.1833877
[5] Yuan KT, Ye JN, Liu ZG, et al. Complement C3 overexpression activates JAK2/STAT3 pathway and correlates with gastric cancer progression[J]. J Exp Clin Cancer Res, 2020, 39(1): 9. doi:10.1186/s13046-019-1514-3
[6] Ding PP, Xu YQ, Li LY, et al. Intracellular complement C5a/C5aR1 stabilizes β-catenin to promote colorectal tumorigenesis[J]. Cell Rep, 2022, 39(9): 110851. doi:10.1016/j.celrep.2022.110851
[7] Kou WX, Li B, Shi Y, et al. High complement protein C1q levels in pulmonary fibrosis and non-small cell lung cancer associated with poor prognosis[J]. BMC Cancer, 2022, 22(1): 110. doi:10.1186/s12885-021-08912-3
[8] Krem MM, Di Cera E. Evolution of enzyme cascades from embryonic development to blood coagulation[J]. Trends Biochem Sci, 2002, 27(2): 67-74. doi:10.1016/s0968-0004(01)02007-2
[9] Revel M, Daugan MV, Sautés-Fridman C, et al. Complement system: promoter or suppressor of cancer progression?[J]. Antibodies(Basel), 2020, 9(4): E57. doi:10.3390/antib9040057
[10] Ferreira VP, Cortes C, Pangburn MK. Native polymeric forms of properdin selectively bind to targets and promote activation of the alternative pathway of complement[J]. Immunobiology, 2010, 215(11): 932-940. doi:10.1016/j.imbio.2010.02.002
[11] Pangburn MK. Initiation of the alternative pathway of complement and the history of “tickover”[J]. Immunol Rev, 2023, 313(1): 64-70. doi:10.1111/imr.13130
[12] Medler TR, Murugan D, Horton W, et al. Complement C5a fosters squamous carcinogenesis and limits T cell response to chemotherapy[J]. Cancer Cell, 2018, 34(4): 561-578.e6. doi:10.1016/j.ccell.2018.09.003
[13] Ricklin D, Reis ES, Mastellos DC, et al. Complement component C3-The “Swiss Army Knife” of innate immunity and host defense[J]. Immunol Rev, 2016, 274(1): 33-58. doi:10.1111/imr.12500
[14] Gonda TA, Tu SP, Wang TC. Chronic inflammation, the tumor microenvironment and carcinogenesis[J]. Cell Cycle, 2009, 8(13): 2005-2013. doi:10.4161/cc.8.13.8985
[15] Maman S, Witz IP. A history of exploring cancer in context[J]. Nat Rev Cancer, 2018, 18(6): 359-376. doi:10.1038/s41568-018-0006-7
[16] Schumacher TN, Thommen DS. Tertiary lymphoid structures in cancer[J]. Science, 2022, 375(6576): eabf9419. doi:10.1126/science.abf9419
[17] Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences[J]. Immunity, 2019, 51(1): 27-41. doi:10.1016/j.immuni.2019.06.025
[18] Pan YY, Yu YD, Wang XJ, et al. Tumor-associated macrophages in tumor immunity[J]. Front Immunol, 2020, 11: 583084. doi:10.3389/fimmu.2020.583084
[19] Yang ML, Cai WS, Lin ZH, et al. Intermittent hypoxia promotes TAM-induced glycolysis in laryngeal cancer cells via regulation of HK1 expression through activation of ZBTB10[J]. Int J Mol Sci, 2023, 24(19): 14808. doi:10.3390/ijms241914808
[20] Jao TM, Wu CZ, Cheng CW, et al. Urokinase plasminogen activator deficiency aggravates cationic bovine serum albumin-induced membranous nephropathy through T helper cell type 2-prone immune response in mice[J]. Lab Invest, 2023, 103(7): 100146. doi:10.1016/j.labinv.2023.100146
[21] Geng YW, Fan J, Chen LY, et al. A notch-dependent inflammatory feedback circuit between macrophages and cancer cells regulates pancreatic cancer metastasis[J]. Cancer Res, 2021, 81(1): 64-76. doi:10.1158/0008-5472.CAN-20-0256
[22] Mastellos DC, Reis ES, Lambris JD. Complement C5a-mediated TAM-ing of antitumor immunity drives squamous carcinogenesis[J]. Cancer Cell, 2018, 34(4): 531-533. doi:10.1016/j.ccell.2018.09.005
[23] Senent Y, Tavira B, Pio R, et al. The complement system as a regulator of tumor-promoting activities mediated by myeloid-derived suppressor cells[J]. Cancer Lett, 2022, 549: 215900. doi:10.1016/j.canlet.2022.215900
[24] Zhang P, Zhang YF, Wang L, et al. Tumor-regulated macrophage type 2 differentiation promotes immunosuppression in laryngeal squamous cell carcinoma[J]. Life Sci, 2021, 267: 118798. doi:10.1016/j.lfs.2020.118798
[25] Nguyen TT, Thanh HD, Do MH, et al. Complement regulatory protein CD46 manifests a unique role in promoting the migration of bladder cancer cells[J]. Chonnam Med J, 2023, 59(3): 160-166. doi:10.4068/cmj.2023.59.3.160
[26] 周一静, 邹建银, 易红良, 等. TGFBI在头颈部鳞状细胞癌中的表达及其临床意义[J]. 山东大学耳鼻喉眼学报, 2023, 37(5): 85-95. doi:10.6040/j.issn.1673-3770.0.2022.459 ZHOU Yijing, ZOU Jianyin, YI Hongliang, et al. Expression of TGFBI in head and neck squamous cell carcinoma and its clinical significance[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2023, 37(5): 85-95. doi:10.6040/j.issn.1673-3770.0.2022.459
[27] Zheng M, Li YM, Liu ZY, et al. Prognostic landscape of tumor-infiltrating T and B cells in human cancer[J]. Front Immunol, 2022, 12: 731329. doi:10.3389/fimmu.2021.731329
[28] Zhang XH, Shi MQ, Chen TL, et al. Characterization of the immune cell infiltration landscape in head and neck squamous cell carcinoma to aid immunotherapy[J]. Mol Ther Nucleic Acids, 2020, 22: 298-309. doi:10.1016/j.omtn.2020.08.030
[29] Kwan WH, van der Touw W, Paz-Artal E, et al. Signaling through C5a receptor and C3a receptor diminishes function of murine natural regulatory T cells[J]. J Exp Med, 2013, 210(2): 257-268. doi:10.1084/jem.20121525
[30] Gadwa J, Bickett TE, Darragh LB, et al. Complement C3a and C5a receptor blockade modulates regulatory T cell conversion in head and neck cancer[J]. J Immunother Cancer, 2021, 9(3): e002585. doi:10.1136/jitc-2021-002585
[31] Cao BR, Wang QF, Zhang H, et al. Two immune-enhanced molecular subtypes differ in inflammation, checkpoint signaling and outcome of advanced head and neck squamous cell carcinoma[J]. Oncoimmunology, 2017, 7(2): e1392427. doi:10.1080/2162402X.2017.1392427
[32] Ding PP, Li L, Li LY, et al. C5aR1 is a master regulator in Colorectal Tumorigenesis via Immune modulation[J]. Theranostics, 2020, 10(19): 8619-8632. doi:10.7150/thno.45058
[33] Wirsing AM, Rikardsen OG, Steigen SE, et al. Characterisation and prognostic value of tertiary lymphoid structures in oral squamous cell carcinoma[J]. BMC Clin Pathol, 2014, 14: 38. doi:10.1186/1472-6890-14-38
[34] Engelhard V, Conejo-Garcia JR, Ahmed R, et al. B cells and cancer[J]. Cancer Cell, 2021, 39(10): 1293-1296. doi:10.1016/j.ccell.2021.09.007
[35] Fridman WH, Petitprez F, Meylan M, et al. B cells and cancer: to B or not to B?[J]. J Exp Med, 2021, 218(1): e20200851. doi:10.1084/jem.20200851
[36] Ruffin AT, Cillo AR, Tabib T, et al. B cell signatures and tertiary lymphoid structures contribute to outcome in head and neck squamous cell carcinoma[J]. Nat Commun, 2021, 12(1): 3349. doi:10.1038/s41467-021-23355-x
[37] 马汝显, 周玲. 鼻腔鼻窦内翻性乳头状瘤组织中HPV/补体C3C4表达及意义[J]. 分子诊断与治疗杂志, 2021, 13(11): 1834-1837. doi:10.19930/j.cnki.jmdt.2021.11.025 MA Ruxian, ZHOU Ling. Expression and significance of HPV/complement C3, C4 in inverted papilloma of nasal cavity and paranasal sinuses[J]. Journal of Molecular Diagnostics and Therapy, 2021, 13(11): 1834-1837. doi:10.19930/j.cnki.jmdt.2021.11.025
[38] Rickert RC. Regulation of B lymphocyte activation by complement C3 and the B cell coreceptor complex[J]. Curr Opin Immunol, 2005, 17(3): 237-243. doi:10.1016/j.coi.2005.03.001
[39] Platt JL, Silva I, Balin SJ, et al. C3d regulates immune checkpoint blockade and enhances antitumor immunity[J]. JCI Insight, 2017, 2(9): e90201. doi:10.1172/jci.insight.90201
[40] Carroll MC. CD21/CD35 in B cell activation[J]. Semin Immunol, 1998, 10(4): 279-286. doi:10.1006/smim.1998.0120
[41] Lu YW, Zhao QY, Liao JY, et al. Complement signals determine opposite effects of B cells in chemotherapy-induced immunity[J]. Cell, 2020, 180(6): 1081-1097.e24. doi:10.1016/j.cell.2020.02.015
[42] Lechner A, Schl??er HA, Thelen M, et al. Tumor-associated B cells and humoral immune response in head and neck squamous cell carcinoma[J]. Oncoimmunology, 2019, 8(3): 1535293. doi:10.1080/2162402X.2018.1535293
[43] Ajona D, Pajares MJ, Chiara MD, et al. Complement activation product C4d in oral and oropharyngeal squamous cell carcinoma[J]. Oral Dis, 2015, 21(7): 899-904. doi:10.1111/odi.12363
[44] Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition[J]. Nat Rev Mol Cell Biol, 2014, 15: 178-196. doi:10.1038/nrm3758
[45] Zhang Y, Weinberg RA. Epithelial-to-mesenchymal transition in cancer: complexity and opportunities[J]. Front Med, 2018, 12(4): 361-373. doi:10.1007/s11684-018-0656-6
[46] Jie XX, Zhang XY, Xu CJ. Epithelial-to-mesenchymal transition, circulating tumor cells and cancer metastasis: mechanisms and clinical applications[J]. Oncotarget, 2017, 8(46): 81558-81571. doi:10.18632/oncotarget.18277
[47] Nuti SV, Mor G, Li PY, et al. TWIST and ovarian cancer stem cells: implications for chemoresistance and metastasis[J]. Oncotarget, 2014, 5(17): 7260-7271. doi:10.18632/oncotarget.2428
[48] Georgakopoulos-Soares I, Chartoumpekis DV, Kyriazopoulou V, et al. EMT factors and metabolic pathways in cancer[J]. Front Oncol, 2020, 10: 499. doi:10.3389/fonc.2020.00499
[49] Yu L, Lu SM, Tian JJ, et al. TWIST expression in hypopharyngeal cancer and the mechanism of TWIST-induced promotion of metastasis[J]. Oncol Rep, 2012, 27(2): 416-422. doi:10.3892/or.2011.1481
[50] Scanlon CS, Van Tubergen EA, Inglehart RC, et al. Biomarkers of epithelial-mesenchymal transition in squamous cell carcinoma[J]. J Dent Res, 2013, 92(2): 114-121. doi:10.1177/0022034512467352
[51] Cho MS, Rupaimoole R, Choi HJ, et al. Complement component 3 is regulated by TWIST1 and mediates epithelial-mesenchymal transition[J]. J Immunol, 2016, 196(3): 1412-1418. doi:10.4049/jimmunol.1501886
[52] Goswami MT, Reka AK, Kurapati H, et al. Regulation of complement-dependent cytotoxicity by TGF-β-induced epithelial-mesenchymal transition[J]. Oncogene, 2016, 35(15): 1888-1898. doi:10.1038/onc.2015.258
[53] Kesselring R, Thiel A, Pries R, et al. The complement receptors CD46, CD55 and CD59 are regulated by the tumour microenvironment of head and neck cancer to facilitate escape of complement attack[J]. Eur J Cancer, 2014, 50(12): 2152-2161. doi:10.1016/j.ejca.2014.05.005
[54] Chen BD, Zhou WY, Tang CF, et al. Down-regulation of C3aR/C5aR inhibits cell proliferation and EMT in hepatocellular carcinoma[J]. Technol Cancer Res Treat, 2020, 19: 1533033820970668. doi:10.1177/1533033820970668
[55] Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation[J]. Cell, 2011, 144(5): 646-674. doi:10.1016/j.cell.2011.02.013
[56] Lin XR, Wu ZY, Hu H, et al. Non-coding RNAs rewire cancer metabolism networks[J]. Semin Cancer Biol, 2021, 75: 116-126. doi:10.1016/j.semcancer.2020.12.019
[57] Suzuki H, Tsukahara T. A view of pre-mRNA splicing from RNase R resistant RNAs[J]. Int J Mol Sci, 2014, 15(6): 9331-9342. doi:10.3390/ijms15069331
[58] Kristensen LS, Hansen TB, Ven? MT, et al. Circular RNAs in cancer: opportunities and challenges in the field[J]. Oncogene, 2018, 37(5): 555-565. doi:10.1038/onc.2017.361
[59] Wang Z, Sun AQ, Yan AH, et al. Circular RNA MTCL1 promotes advanced laryngeal squamous cell carcinoma progression by inhibiting C1QBP ubiquitin degradation and mediating beta-catenin activation[J]. Mol Cancer, 2022, 21(1): 92. doi:10.1186/s12943-022-01570-4
[60] Dai XF, Ye YJ, He FL. Emerging innovations on exosome-based onco-therapeutics[J]. Front Immunol, 2022, 13: 865245. doi:10.3389/fimmu.2022.865245
[61] Whiteside TL. Tumor-derived exosomes and their role in tumor-induced immune suppression[J]. Vaccines, 2016, 4(4): 35. doi:10.3390/vaccines4040035
[62] Zhang HR, Lu J, Liu J, et al. Advances in the discovery of exosome inhibitors in cancer[J]. J Enzyme Inhib Med Chem, 2020, 35(1): 1322-1330. doi:10.1080/14756366.2020.1754814
[63] Li T, Li J, Wang HT, et al. Exosomes: potential biomarkers and functions in head and neck squamous cell carcinoma[J]. Front Mol Biosci, 2022, 9: 881794. doi:10.3389/fmolb.2022.881794
[64] Theodoraki MN, Yerneni SS, Hoffmann TK, et al. Clinical significance of PD-L1+ exosomes in plasma of head and neck cancer patients[J]. Clin Cancer Res, 2018, 24(4): 896-905. doi:10.1158/1078-0432.CCR-17-2664
[65] Wang JT, Zhou YD, Lu JG, et al. Combined detection of serum exosomal miR-21 and HOTAIR as diagnostic and prognostic biomarkers for laryngeal squamous cell carcinoma[J]. Med Oncol, 2014, 31(9): 148. doi:10.1007/s12032-014-0148-8
[66] Abu-Humaidan AHA, Ekblad L, Wennerberg J, et al. EGFR modulates complement activation in head and neck squamous cell carcinoma[J]. BMC Cancer, 2020, 20(1): 121. doi:10.1186/s12885-020-6615-z
[67] Bushey RT, Gottlin EB, Campa MJ, et al. Complement factor H protects tumor cell-derived exosomes from complement-dependent lysis and phagocytosis[J]. PLoS One, 2021, 16(6): e0252577. doi:10.1371/journal.pone.0252577
[68] Liu XM, Wang P, Zhang CY, et al. Epidermal growth factor receptor(EGFR): a rising star in the era of precision medicine of lung cancer[J]. Oncotarget, 2017, 8(30): 50209-50220. doi:10.18632/oncotarget.16854
[69] 朱晓城, 钱晓云, 顾亚军, 等. MGMT和EGFR蛋白在喉鳞状细胞癌中的表达及临床意义[J]. 山东大学耳鼻喉眼学报, 2017, 31(4): 68-72. doi:10.6040/j.issn.1673-3770.0.2017.116 ZHU Xiaocheng, QIAN Xiaoyun, GU Yajun, et al. Expression and clinical value of MGMT and EGFR in laryngeal squamous cell carcinoma[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2017, 31(4): 68-72. doi:10.6040/j.issn.1673-3770.0.2017.116
[1] 沈文浩,陈曦. 双能CT在喉鳞状细胞癌诊疗中的运用[J]. 山东大学耳鼻喉眼学报, 2025, 39(5): 156-160.
[2] 杨鸣,刘雪霞,张华. m6A识别蛋白IGF2BPs家族在头颈肿瘤中的研究进展[J]. 山东大学耳鼻喉眼学报, 2025, 39(3): 153-161.
[3] 张茂华,魏日富,朱忠寿,刘平,高尚,李慧凤. LncRNA PCAT-1对鼻咽癌细胞生物学行为及化疗敏感性的影响[J]. 山东大学耳鼻喉眼学报, 2025, 39(1): 68-76.
[4] 吴彬,周敬淳. 单细胞测序分析喉鳞状细胞癌细胞RPN2表达模式[J]. 山东大学耳鼻喉眼学报, 2024, 38(3): 1-11.
[5] 王凯健,陈雪生,王威. 血小板-淋巴细胞比值与喉鳞状细胞癌预后相关性的Meta分析[J]. 山东大学耳鼻喉眼学报, 2024, 38(3): 67-73.
[6] 宋斐,宋昊,李玉梅,牟亚魁,宋西成. 肿瘤源性外泌体在头颈鳞状细胞癌微环境中的免疫调节作用[J]. 山东大学耳鼻喉眼学报, 2024, 38(1): 92-100.
[7] 张永红,张辉,王彩华,杨欣欣,吴允刚,赵玉凤,庞太忠,李晓瑜. 基于TCGA数据库构建喉鳞状细胞癌免疫相关基因预后模型及筛选靶向分子药物[J]. 山东大学耳鼻喉眼学报, 2023, 37(5): 54-62.
[8] 李亚楠,梁辉. 人乳头瘤病毒相关口咽鳞状细胞癌发生机制的研究进展[J]. 山东大学耳鼻喉眼学报, 2023, 37(3): 104-110.
[9] 乔新杰,赵玉林. 慢性鼻窦炎中上皮间质转化信号转导通路及其他相关因子的研究进展[J]. 山东大学耳鼻喉眼学报, 2022, 36(3): 71-77.
[10] 黄丹怡,张婷,陈静,张薇. 上皮屏障在慢性鼻窦炎伴鼻息肉中的研究进展[J]. 山东大学耳鼻喉眼学报, 2022, 36(3): 78-83.
[11] 刘勇,袁存立,曹慧,郑成彩,晁方, 许风雷. CHD1L通过EMT促进喉鳞状细胞癌细胞的增殖、侵袭和转移[J]. 山东大学耳鼻喉眼学报, 2022, 36(2): 32-39.
[12] 王俊鑫,孙岩. miRNA-29b参与上皮间质转化相关信号通路调控的研究进展[J]. 山东大学耳鼻喉眼学报, 2021, 35(6): 132-137.
[13] 范义燕,张肖林,刘秀珍,尹晶晶,袁进,王延飞,陈军. CPS1在喉鳞癌组织中的表达及临床意义[J]. 山东大学耳鼻喉眼学报, 2020, 34(6): 72-76.
[14] 陈慧君,宋圣花,董伟达,周涵. 术前外周血纤维蛋白原水平对喉癌预后的影响[J]. 山东大学耳鼻喉眼学报, 2020, 34(2): 110-114.
[15] 朱晓城,钱晓云,顾亚军,沈晓辉,宋盼盼,李惠,高下. MGMT和EGFR蛋白在喉鳞状细胞癌中的表达及临床意义[J]. 山东大学耳鼻喉眼学报, 2017, 31(4): 68-72.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
网站版权所有 © 2018 《山东大学耳鼻喉眼学报》编辑部　
地址：山东省济南市山大南路27号（250100）电话：+86-0531-88366912 E-mail: ebhxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发